Part, Chapter, Paragraph
1 I, 2. 1 | at macroeconomic level (Figure 2.1).~ ~ ~ ~The analysis
2 I, 2. 2 | study estimates that the figure amounts to about 260 million
3 I, 2. 4 | Product. The data reported in Figure 2.2 clearly show that large
4 I, 2. 4 | joined the EU in 2004.~ ~Figure 2.2. Gross Domestic Product
5 I, 2. 5 | achieved since the 80s. Figure 2.3 shows the significant
6 I, 2. 6 | total early school leavers (Figure 2.4).~ ~Table 2.3. Total
7 I, 2. 6 | national educational systems.~ ~Figure 2.4. Early school leavers
8 I, 2. 6 | and the Czech Republic the figure was under 40%. Women outnumbered
9 I, 2. 7 | urban areas. By 2030, this figure is expected to increase
10 I, 3. 1 | its own fertility history (Figure 3.1)~ ~Figure 3.1. Total
11 I, 3. 1 | fertility history (Figure 3.1)~ ~Figure 3.1. Total Period Fertility
12 I, 3. 2 | was in Bulgaria (-5%).~ ~Figure 3.2. Population size per
13 I, 3. 2 | States in the coming decades (Figure 3.2). Based on the EUROPOP
14 I, 3. 2 | that in the former EU15 (Figure 3.3).~ ~Figure 3.3. Natural
15 I, 3. 2 | former EU15 (Figure 3.3).~ ~Figure 3.3. Natural increase rate
16 I, 3. 3 | life expectancy changes.~ ~Figure 3.4. Age composition in
17 I, 3. 3 | composition in EU27 in 2006~ ~Figure 3.5. Age composition in
18 I, 3. 3 | the end of that period (Figure 3.4 and Figure 3.5). Since
19 I, 3. 3 | that period (Figure 3.4 and Figure 3.5). Since population pyramids
20 I, 3. 3 | with this trend in ageing. Figure 3.5.3 shows the percentage
21 I, 3. 3 | within the coming decade.~ ~Figure 3.6. Share of EU27 population
22 I, 3. 3 | and did not change much (Figure 14). Poland, Slovakia, Bulgaria,
23 I, 3. 3 | Belgium have the smallest. Figure 15 shows that currently
24 I, 3. 3 | to the current 4.2%. A figure of 6.6% is expected in 2025.
25 II, 4. 1 | Figures 4.1.1. and 4.1.2.~ ~Figure 4.1.1. Life Expectancy,
26 II, 4. 1 | Limitations, in 2005, Men~ ~Figure 4.1.2. Life Expectancy,
27 II, 4. 2 | mortality at high ages.~ ~Figure 4.2.1. Standardized death
28 II, 4. 2 | convergence is completed.~ ~Figure 4.2.2. Relationship between
29 II, 4. 2 | significant relationship (Figure 4.2.3). However, this is
30 II, 4. 2 | Eastern European countries.~ ~Figure 4.2.3. Relationship between
31 II, 4. 2 | increase since 1970 for menl (Figure 4.2.4). The regression coefficient
32 II, 4. 2 | will take some 40 years.~ ~Figure 4.2.4. Relationship between
33 II, 4. 2 | stronger (if we compare Figure 4.2.5 with Figure 4.2.2).
34 II, 4. 2 | compare Figure 4.2.5 with Figure 4.2.2). In that case the
35 II, 4. 2 | convergence will take 30 years.~ ~Figure 4.2.5. Relationship between
36 II, 5. 1. 1 | as in each Member States (Figure 5.1.1). At individual level,
37 II, 5. 1. 1 | management for all conditions.~ ~Figure 5.1.1a. Proportion of cardiovascular
38 II, 5. 1. 1 | 2003), EU27 – A) Women~ ~Figure 5.1.1b. Proportion of cardiovascular
39 II, 5. 2. 3 | causes of deaths in EU (Figure 5.1.1). Around half of the
40 II, 5. 2. 3 | IHD in men are shown in Figure 5.2.1: in all countries
41 II, 5. 2. 3 | results can be found in women (Figure 5.2.2) for whom mortality
42 II, 5. 2. 3 | 40 to 23 per 100.000).~ ~Figure 5.2.1. Age-standardized
43 II, 5. 2. 3 | Men aged 35-74 years~ ~Figure 5.2.2. Age-standardized
44 II, 5. 2. 3 | stroke in men are shown in Figure 5.2.3; from 1994 to 2003
45 II, 5. 2. 3 | Europe and Eastern Europe.~ ~Figure 5.2.3. Age-standardized (
46 II, 5. 2. 3 | results can be found in women (Figure 5.2.4) for which mortality
47 II, 5. 2. 3 | Eastern Europe countries.~ ~Figure 5.2.4. Age-standardized (
48 II, 5. 3. 5 | 482 new cases per 100,000, Figure 5.3.2a) and in Northern
49 II, 5. 3. 5 | 351 new cases per 100,000, Figure 5.3.2b), while the highest
50 II, 5. 3. 5 | 287 deaths per 100,000, Figure 5.3.4a) and again in Northern
51 II, 5. 3. 5 | 155 deaths per 100,000, Figure 5.3.4b).~Figures 5.3.2 show
52 II, 5. 3. 5 | or constant for women.~ ~Figure 5.3.1a. All cancer (ICD9
53 II, 5. 3. 5 | standard) by sex in 2006 A) Men~Figure 5.3.1b. All cancer (ICD9
54 II, 5. 3. 5 | by sex in 2006 B) Women~ ~Figure 5.3.2a. Trends of all cancer (
55 II, 5. 3. 5 | standard) by sex A) Men~Figure 5.3.2b. Trends of all cancer (
56 II, 5. 3. 5 | standard) by sex B) Women~ ~ ~Figure 5.3.3a. All cancer (ICD9
57 II, 5. 3. 5 | standard) by sex in 2006 A) Men~Figure 5.3.3b. All cancer (ICD9
58 II, 5. 3. 5 | by sex in 2006 B) Women~ ~Figure 5.3.4a. Trends of all cancer (
59 II, 5. 3. 5 | standard) by sex A) Men~Figure 5.3.4b. Trends of all cancer (
60 II, 5. 3. 5 | incidence and mortality.~ ~Figure 5.3.5a. Stomach cancer (
61 II, 5. 3. 5 | standard) by sex in 2006 A) Men~Figure 5.3.5b. Stomach cancer (
62 II, 5. 3. 5 | by sex in 2006 B) Women~ ~Figure 5.3.6a. Trends of stomach
63 II, 5. 3. 5 | standard) by sex A) Men~Figure 5.3.6b. Trends of stomach
64 II, 5. 3. 5 | standard) by sex B) Women~ ~Figure 5.3.7a. Stomach cancer (
65 II, 5. 3. 5 | standard) by sex in 2006 A) Men~Figure 5.3.7b. Stomach cancer (
66 II, 5. 3. 5 | by sex in 2006 B) Women~ ~Figure 5.3.8a. Trends of stomach
67 II, 5. 3. 5 | standard) by sex A) Men~Figure 5.3.8b. Trends of stomach
68 II, 5. 3. 5 | Eastern Europe mainly for men (Figure 5.3.10a). Male mortality
69 II, 5. 3. 5 | Male mortality rates (Figure 5.3.12a) are declining in
70 II, 5. 3. 5 | Eastern and Southern Europe.~ ~Figure 5.3.9a. Colorectal cancer (
71 II, 5. 3. 5 | standard) by sex in 2006 A) Men~Figure 5.3.9b. Colorectal cancer (
72 II, 5. 3. 5 | by sex in 2006 B) Women~ ~Figure 5.3.10a. Trends of colorectal
73 II, 5. 3. 5 | standard) by sex A) Men~Figure 5.3.10b. Trends of colorectal
74 II, 5. 3. 5 | standard) by sex B) Women~ ~Figure 5.3.11a. Colorectal cancer (
75 II, 5. 3. 5 | standard) by sex in 2006 A) Men~Figure 5.3.11b. Colorectal cancer (
76 II, 5. 3. 5 | by sex in 2006 B) Women~ ~Figure 5.3.12a. Trends of colorectal
77 II, 5. 3. 5 | standard) by sex A) Men~Figure 5.3.12b. Trends of colorectal
78 II, 5. 3. 5 | maximum levels of incidence (Figure 5.3.14a) and mortality (
79 II, 5. 3. 5 | 5.3.14a) and mortality (Figure 5.3.16a) rates (in respect
80 II, 5. 3. 5 | had the maximum incidence (Figure 5.3.14b) and mortality (
81 II, 5. 3. 5 | 5.3.14b) and mortality (Figure 5.3.16b) rates for women (
82 II, 5. 3. 5 | are increasing for women (Figure 5.3.14b and 5.3.16b).~ ~
83 II, 5. 3. 5 | 5.3.14b and 5.3.16b).~ ~Figure 5.3.13a. Lung cancer (ICD9
84 II, 5. 3. 5 | standard) by sex in 2006 A) Men~Figure 5.3.13b. Lung cancer (ICD9
85 II, 5. 3. 5 | by sex in 2006 B) Women~ ~Figure 5.3.14a. Trends of lung
86 II, 5. 3. 5 | standard) by sex A) Men~Figure 5.3.14b. Trends of lung
87 II, 5. 3. 5 | standard) by sex B) Women~ ~Figure 5.3.15a. Lung cancer (ICD9
88 II, 5. 3. 5 | standard) by sex in 2006 A) Men~Figure 5.3.15b. Lung cancer (ICD9
89 II, 5. 3. 5 | by sex in 2006 B) Women~ ~Figure 5.3.16a. Trends of lung
90 II, 5. 3. 5 | standard) by sex A) Men~Figure 5.3.16b. Trends of lung
91 II, 5. 3. 5 | screening implementation.~Figure 5.3.17 shows that the maximum
92 II, 5. 3. 5 | be associated with GDP.~Figure 5.3.19 shows that in 2007
93 II, 5. 3. 5 | Denmark). Mortality trends (Figure 5.3.20) are decreasing in
94 II, 5. 3. 5 | constant in Eastern Europe.~ ~Figure 5.3.17. Female breast cancer (
95 II, 5. 3. 5 | European standard) in 2006~Figure 5.3.18. Trends of female
96 II, 5. 3. 5 | rates (European standard)~Figure 5.3.19. Female breast cancer (
97 II, 5. 3. 5 | European standard) in 2006~Figure 5.3.20. Trends of female
98 II, 5. 3. 5 | negatively associated with GDP (Figure 5.3.21). This could be caused
99 II, 5. 3. 5 | Southern and Northern Europe (Figure 5.3.22 and Figure 5.3.24)
100 II, 5. 3. 5 | Europe (Figure 5.3.22 and Figure 5.3.24) where there are
101 II, 5. 3. 5 | well-developed screening programs.~ ~Figure 5.3.21. Cervical cancer (
102 II, 5. 3. 5 | European standard) in 2002~Figure 5.3.22. Trends of cervical
103 II, 5. 3. 5 | rates (European standard)~Figure 5.3.23. Uterus cancer standardized
104 II, 5. 3. 5 | class 20-44 in 1996-2001~Figure 5.3.24. Trends of uterus
105 II, 5. 3. 5 | positively associated with GDP (Figure 5.3.25) possibly due to
106 II, 5. 3. 5 | Northern and Southern Europe (Figure 5.3.26) reflects the PSA
107 II, 5. 3. 5 | Mortality rates by years (Figure 5.3.28) are constant in
108 II, 5. 3. 5 | increasing in Eastern Europe.~ ~Figure 5.3.25. Prostate cancer (
109 II, 5. 3. 5 | European standard) in 2006~Figure 5.3.26. Trends of prostate
110 II, 5. 3. 5 | rates (European standard)~Figure 5.3.27. Prostate cancer (
111 II, 5. 3. 5 | European standard) in 2006~Figure 5.3.28. Trends of prostate
112 II, 5. 3. 6 | Europe (Sant et al, 2003).~ ~Figure 5.3.29a. All cancers (ICD9
113 II, 5. 3. 6 | 31st December 1999 A) Men~Figure 5.3.29b. All cancers (ICD9
114 II, 5. 3. 6 | mortality (Sant et al, 2003).~ ~Figure 5.3.30a. Stomach cancer (
115 II, 5. 3. 6 | 31st December 1999 A) Men~Figure 5.3.30b. Stomach cancer (
116 II, 5. 3. 6 | sites (Sant et al, 2003).~ ~Figure 5.3.31a. Colorectal cancer (
117 II, 5. 3. 6 | 31st December 1999 A) Men~Figure 5.3.31b. Colorectal cancer (
118 II, 5. 3. 6 | women (Sant et al, 2003).~ ~Figure 5.3.32a. Lung cancer (ICD9
119 II, 5. 3. 6 | 31st December 1999 A) Men~Figure 5.3.32b. Lung cancer (ICD9
120 II, 5. 3. 6 | year relative survival (Figure 5.3.33) exceeding 75% in
121 II, 5. 3. 6 | Coleman et al, 2003).~ ~Figure 5.3.33. Female breast cancer (
122 II, 5. 3. 6 | higher in Sweden (70%) (Figure 5.3.34) (Sant et al, 2003).
123 II, 5. 3. 6 | Coleman et al, 2003).~ ~Figure 5.3.34. Cervical cancer (
124 II, 5. 3. 6 | diagnosis stood at 67% (Figure 5.3.35). 5-year relative
125 II, 5. 3. 6 | Coleman et al, 2003).~ ~Figure 5.3.35. Prostate cancer (
126 II, 5. 4. 1 | diabetes with a current figure of 40.9 million, followed
127 II, 5. 4. 1 | over the next 20 years. (Figure 5.4.1). The latest edition
128 II, 5. 4. 1 | King 1998; Wild 2004).~ ~Figure 5.4.1. The Growing Diabetes
129 II, 5. 4. 3 | only Germany provided a figure of 52%.~Control of serum
130 II, 5. 4. 4 | countries approach at least a figure of 20%. Overweight and obesity,
131 II, 5. 4. 4 | emergency dictated by this figure should be rather obvious
132 II, 5. 4. 4 | coding practices. The average figure obtained by EUCID should
133 II, 5. 5. 1 | diseases and diabetes.~ ~Figure 5.5.1.1. Relative burden
134 II, 5. 5. 1 | Hungary and Croatia).~ ~Figure 5.5.1.2. Odds ratio (with
135 II, 5. 5. 1 | Slovakia and Latvia.~ ~Figure 5.5.1.3. Odds ratio (with
136 II, 5. 5. 1 | risk than younger adults.~ ~Figure 5.5.1.4. Odds ratio (with
137 II, 5. 5. 1 | Greece, Malta and Italy (Figure 5.5.1.5).~ ~Figure 5.5.1.
138 II, 5. 5. 1 | Italy (Figure 5.5.1.5).~ ~Figure 5.5.1.5. Death due to suicide
139 II, 5. 5. 2 | Alzheimer Europe, 2006a). Figure 5.5.2.1.1 uses the statistics
140 II, 5. 5. 2 | ageing of the population.~ ~Figure 5.5.2.1. The number of people
141 II, 5. 5. 3 | Prevalence and Incidence~Figure 5.5.3.2.1. Estimated prevalence
142 II, 5. 5. 3 | countries are missing in figure 5.5.3.3.2 due to lacking
143 II, 5. 5. 3 | collection and documentation.~Figure 5.5.3.2.2. Inter-country
144 II, 5. 5. 3 | Schizophrenia ICD-10 codes: F20.~Figure 5.5.3.2.3. Admission rates
145 II, 5. 5. 3 | rate still remains high.~Figure 5.5.3.2.4. Average length
146 II, 5. 5. 3 | per 1,000 populations (see Figure 5.5.3.3.2), the value reported
147 II, 5. 5. 3 | atypicals (Knapp et al, 2007) (Figure 5.5.3.3.5).~Figure 5.5.3.
148 II, 5. 5. 3 | 2007) (Figure 5.5.3.3.5).~Figure 5.5.3.2.5: Prescription
149 II, 5. 5. 3 | with patients’ relatives) (Figure 5.5.3.3.6). Internalized
150 II, 5. 5. 3 | chronic course of disease.~Figure 5.5.3.2.6. Experiences of
151 II, 5. 5. 3 | evaluated by Andlin-Sobocki (Figure 5.5.3.3.7), it can be assumed
152 II, 5. 5. 3 | with respect to F20-F29~Figure 5.5.3.2.7. Direct healthcare
153 II, 5. 5. 3 | European Brain Council (Figure 5.5.3.3.8). Although not
154 II, 5. 5. 3 | not taken into account.~Figure 5.5.3.2.8. Costs per case
155 II, 5. 5. 3 | annually, yet for adults the figure is £25 billion (Euros 36.
156 II, 5. 5. 3 | reported in Table 5.5.3.5.5 and Figure 5.5.3.5.1. RR-MS ranged
157 II, 5. 5. 3 | shown in Table 5.5.3.5.6 and Figure 5.5.3.5.2. The estimated
158 II, 5. 5. 3 | activities of daily living.~ ~Figure 5.5.3.5.1. Distribution
159 II, 5. 5. 3 | the European community (Figure 5.5.3.6.1. Estimated total
160 II, 5. 5. 3 | Parkinson’s disease in Europe~ ~Figure 5.5.3.6.1. Estimated total
161 II, 5. 5. 3 | countries including PD (Figure 5.5.3.6.2) (Andlin-Sobocki
162 II, 5. 5. 3 | per patient of €7,600.~ ~Figure 5.5.3.6.2. Cost per case
163 II, 5. 5. 3 | HY scale in five groups (Figure 5.5.3.6.3). In the early
164 II, 5. 5. 3 | per patient (HY IV).~ ~ ~Figure 5.5.3.6.3. Cost of Parkinson’
165 II, 5. 5. 3 | disease onset, and this figure rose to 80% five to nine
166 II, 5. 6. 3 | 2001; Hagen et al, 1997) (Figure 5.6.1), explained partly
167 II, 5. 6. 3 | prevalent with older age (Figure 5.6.2). A decline in the
168 II, 5. 6. 3 | of the working place.~ ~Figure 5.6.1. The age and sex-specific
169 II, 5. 6. 3 | respondents (n=2755) in Sweden~ ~ ~Figure 5.6.2. Prevalence of self
170 II, 5. 6. 3 | group in the Netherlands~ ~Figure 5.6.2.b Prevalence of self
171 II, 5. 6. 3 | selected European Countries ~ ~Figure 5.6.3. Prevalence of knee
172 II, 5. 6. 3 | Prevalence of knee OA in Europe~ ~Figure 5.6.4a. Prevalence of radiographic
173 II, 5. 6. 3 | radiographic OA by age A) Men~Figure 5.6.4b. Prevalence of radiographic
174 II, 5. 7. 1 | biomarkers at population level.~ ~Figure 5.7.1. Development and progression
175 II, 5. 7. 3 | range) the corresponding figure was 7.7 cases /year pmarp (<
176 II, 5. 7. 3 | m2 ), the corresponding figure was 21 cases pmarp (Esbjorner
177 II, 5. 7. 3 | Epirce, 2007) is shown in Figure 5.7.2.~ ~Figure 5.7.2. Prevalence
178 II, 5. 7. 3 | shown in Figure 5.7.2.~ ~Figure 5.7.2. Prevalence of chronic
179 II, 5. 7. 3 | et al, 2005) in females (Figure 5.7.3), while higher figures
180 II, 5. 7. 3 | CKD increased with age (Figure 5.7.4).~ ~Figure 5.7.3.
181 II, 5. 7. 3 | with age (Figure 5.7.4).~ ~Figure 5.7.3. Prevalence of stages
182 II, 5. 7. 3 | selected EUGLOREH countries.~ ~Figure 5.7.4. Sex and age specific
183 II, 5. 8. 3 | Slovakia, Romania, Hungary (Figure 5.8.1).~ ~ ~ ~In two model
184 II, 5. 8. 3 | results are reported in Figure 5.8.2.~ ~Figure 5.8.2. Prevalence
185 II, 5. 8. 3 | reported in Figure 5.8.2.~ ~Figure 5.8.2. Prevalence of the
186 II, 5. 8. 4 | smoking habit is presented in Figure 5.8.3.~ ~Figure 5.8.3. Incidence
187 II, 5. 8. 4 | presented in Figure 5.8.3.~ ~Figure 5.8.3. Incidence rates of
188 II, 5. 9. FB | spontaneously with age (Figure 5.FB.1).~ ~Figure 5.FB.1.
189 II, 5. 9. FB | with age (Figure 5.FB.1).~ ~Figure 5.FB.1. Symptoms of allergic
190 II, 5. 9. 3 | adulthood and childhood.~ ~Figure 5.9.1. Wheeze in last 12
191 II, 5. 9. 3 | ISAAC phase I by country~ ~Figure 5.9.2. Asthma ever in ECHRS
192 II, 5. 9. 3 | ISAAC phase I by country.~ ~Figure 5.9.3. Asthma by age 14
193 II, 5. 9. 3 | ISAAC phase I by country~ ~Figure 5.9.4. Hay fever in ECHRS
194 II, 5. 9. 3 | Authors themselves, this figure is much lower than the prevalence
195 II, 5. 9. 3 | been observed since 1994(Figure 5.9.5.)~ ~ ~ ~The costs
196 II, 5. 10. 1 | on unknown mechanisms.~ ~Figure 5.10.1. Classification of
197 II, 5. 10. 3 | corresponding to Sweden (18%) (Figure 5.10.2). The most commonly
198 II, 5. 10. 3 | 12% (Rona et al, 2007).~ ~Figure 5.10.2. Reported food allergy/
199 II, 5. 10. 3 | food allergy worldwide (Figure 5.10.3), with an overall
200 II, 5. 10. 3 | Fasano and Catassi, 2001).~ ~Figure 5.10.3. Prevalence of celiac
201 II, 5. 11. 3 | ill-defined subtypes; this figure is higher than for that
202 II, 5. 14. 3 | whilethe corresponding figure for Denmark is 1.0 DMF-T.~ ~
203 II, 5. 14. 3 | of tooth loss in Europe (Figure 5.14.1). Edentulous prevalence
204 II, 5. 14. 3 | disappear in the future.~ ~ ~Figure 5.14.1. Edentulous people
205 II, 5. 14. 3 | affects 10% to 15% of adults (Figure 5.14.2). According to the
206 II, 5. 14. 3 | moderate and 4% severe.~ ~Figure 5.14.2. Adults aged 35-44
207 II, 5. 14. 3 | of oral health services. Figure 5.14.3 illustrates the difference
208 II, 5. 14. 3 | 58.3% at the age of12.~ ~Figure 5.14.3. Children aged 12
209 II, 6. 2. 0(2) | specified; the official total figure has been used for the other
210 II, 6. 3. 2 | as low baseline figures (figure 6.1). However, two countries (
211 II, 6. 3. 2 | may not be irreversible.~ ~Figure 6.1. Proportion of methicillin-resistant
212 II, 6. 3. 2 | methycillin-sensitive Staphylococcus aureus (Figure 6.1), Pseudomonas aeruginosa,
213 II, 6. 3. 3 | and EEA/EFTA countries (Figure 6.2). The epidemic exhibits
214 II, 6. 3. 3 | in the Netherlands.~ ~ ~Figure 6.2. HIV cases per million.~
215 II, 6. 3. 3 | risen steadily since then (figure 6.3). In 2005, a total of
216 II, 6. 3. 3 | in men than in women.~ ~Figure 6.3. Trends of Gonorrhoea
217 II, 6. 3. 4 | cases of tubercolosis~ ~ ~ ~Figure 6.A1.1 TB cases per 100,
218 II, 6. 3. 4 | selected countries and EU 25~Figure 6.A1.2 Tubercolosis cases
219 II, 6. 3. 4 | by age and gender~ ~ ~ ~Figure 6.A1.3 Combined MDR in 2005~ ~ ~ ~ ~
220 II, 6. 3. 4 | Combined MDR in 2005~ ~ ~ ~ ~Figure 6.A1.4 New culture positive
221 II, 6. 3. 4 | especially among elderly (figure 6.4) and immuno-compromised
222 II, 6. 3. 4 | effectively with antibiotics.~ ~Figure 6.4. Trends of legionellosis
223 II, 6. 3. 5 | the new EU Member States (figure 6.5).~ ~Figure 6.5. Measles (
224 II, 6. 3. 5 | Member States (figure 6.5).~ ~Figure 6.5. Measles (MCV1) vaccine
225 II, 6. 3. 5 | 000 per year after 1998 (Figure 6.6).~ ~Figure 6.6. Measles
226 II, 6. 3. 5 | after 1998 (Figure 6.6).~ ~Figure 6.6. Measles trend in Europe
227 II, 6. 3. 6 | result of better reporting (Figure 6.7). The most affected
228 II, 6. 3. 6 | fluoroquinolones and tetracycline.~ ~Figure 6.7. Campylobacteriosis
229 II, 6. 3. 7 | steady decrease since 2000 (Figure 6.8).~ ~Figure 6.8. Malaria
230 II, 6. 3. 7 | since 2000 (Figure 6.8).~ ~Figure 6.8. Malaria trends in Europe~ ~
231 II, 7. 3. 2 | level as in the Netherlands (Figure 7.1).~ ~Figure 7.1. Injury
232 II, 7. 3. 2 | Netherlands (Figure 7.1).~ ~Figure 7.1. Injury death rates
233 II, 7. 3. 2 | of undetermined intent (Figure 7.2).~ ~Figure 7.2. Fatal
234 II, 7. 3. 2 | undetermined intent (Figure 7.2).~ ~Figure 7.2. Fatal injuries by causes
235 II, 7. 3. 2 | fatalities are male, 34% female (Figure 7.3).~ ~Figure 7.3. Injury
236 II, 7. 3. 2 | female (Figure 7.3).~ ~Figure 7.3. Injury deaths per 100
237 II, 7. 3. 2 | decline of injury mortality (Figure 7.4).~ ~Figure 7.4. Selected
238 II, 7. 3. 2 | mortality (Figure 7.4).~ ~Figure 7.4. Selected causes of
239 II, 7. 3. 3 | billions of healthcare costs (Figure 7.5).~ ~Figure 7.5. Hospital
240 II, 7. 3. 3 | healthcare costs (Figure 7.5).~ ~Figure 7.5. Hospital discharges
241 II, 7. 3. 4 | approach to injury prevention (Figure 7.6).~ ~Figure 7.6. Unintentional
242 II, 7. 3. 4 | prevention (Figure 7.6).~ ~Figure 7.6. Unintentional fatal
243 II, 7. 3. 4 | mortality in some Member States (Figure 7.7).~ ~Figure 7.7. Road
244 II, 7. 3. 4 | Member States (Figure 7.7).~ ~Figure 7.7. Road fatalities and
245 II, 7. 3. 4 | 40% of road fatalities (Figure 7.8).Even the high share
246 II, 7. 3. 4 | SafetyNet project (htt ~ ~Figure 7.8. Fatalities per road
247 II, 7. 3. 4 | sustain slight injuries (Figure 7.9).~ ~Figure 7.9. Non–
248 II, 7. 3. 4 | injuries (Figure 7.9).~ ~Figure 7.9. Non–fatal road traffic
249 II, 7. 3. 4 | registration practices (Figure 7.10).~ ~Figure 7.10. Fatalities
250 II, 7. 3. 4 | practices (Figure 7.10).~ ~Figure 7.10. Fatalities and injured
251 II, 7. 3. 4 | traffic safety institutions (Figure 7.11).~ ~ ~Figure 7.11.
252 II, 7. 3. 4 | institutions (Figure 7.11).~ ~ ~Figure 7.11. Fatalities at work
253 II, 7. 3. 4 | described in Chapter 6.2. Figure 7.12. Non-fatal work place
254 II, 7. 3. 4 | of lost working days.~ ~Figure 7.12. Non-fatal work place
255 II, 7. 3. 4 | be treated in hospital (Figure 7.13).~ ~Figure 7.13. Fatalities
256 II, 7. 3. 4 | hospital (Figure 7.13).~ ~Figure 7.13. Fatalities and injured
257 II, 7. 3. 4 | of this injury sector (Figure 7.14).~ ~Figure 7.14. Non
258 II, 7. 3. 4 | sector (Figure 7.14).~ ~Figure 7.14. Non fatal (hospital
259 II, 7. 3. 5 | 000 people a year – see Figure 7.2 ) In Europe suicide
260 II, 7. 3. 5 | per 100 000 in Lithuania (Figure 7.15.A).~ ~Figure 7.15.a.
261 II, 7. 3. 5 | Lithuania (Figure 7.15.A).~ ~Figure 7.15.a. Suicide and self
262 II, 7. 3. 5 | suicide in the European Union (Figure 7.15.b. Suicide and intentional
263 II, 7. 3. 5 | commit more suicide attempts (Figure 7.16).~ ~Figure 7.15.b.
264 II, 7. 3. 5 | attempts (Figure 7.16).~ ~Figure 7.15.b. Suicide and intentional
265 II, 7. 3. 5 | attempts and self-harm.~ ~Figure 7.16. Hospital deaths and
266 II, 7. 3. 5 | preventability of violence (Figure 7.17).~ ~Like many other
267 II, 7. 3. 5 | are victims of violence (Figure 7.17. Homicide, assault
268 II, 7. 3. 5 | selected EUGLOREH countries).~ ~Figure 7.17. Homicide, assault
269 II, 7. 4. 1 | higher in very young ages (Figure 7.18). Injury is the leading
270 II, 7. 4. 1 | Safety Promotion, 2008).~ ~Figure 7.18. Injury death in %
271 II, 7. 4. 1 | injury deaths in children (Figure 7.19.A).~ ~Figure 7.19.a.
272 II, 7. 4. 1 | children (Figure 7.19.A).~ ~Figure 7.19.a. Fatal injuries by
273 II, 7. 4. 1 | Kumpala & Paavola 2008); this figure represents 65% of all young
274 II, 7. 4. 1 | causes for injury deaths (Figure 7.19.B).~ ~Figure 7.19.b.
275 II, 7. 4. 1 | deaths (Figure 7.19.B).~ ~Figure 7.19.b. Fatal injuries by
276 II, 7. 4. 2 | people aged 65 and over (Figure 7.3) with falls being the
277 II, 7. 4. 2 | major cause of these deaths (Figure 7.19.C). Injuries, at an
278 II, 7. 4. 2 | prevention actions are taken.~ ~Figure 7.19.c. Fatal injuries by
279 II, 7. 4. 3 | highest risk of an injury (Figure 7.20; see also Figure 7.
280 II, 7. 4. 3 | injury (Figure 7.20; see also Figure 7.8. Fatalities per road
281 II, 7. 4. 3 | falls in transport areas.~ ~Figure 7.20. Mortality of Vulnerable
282 II, 7. 4. 4 | to sports activities (see Figure 7.14).This means that an
283 II, 7. 4. 4 | and aerobics (7%). (see Figure 7.21).Swimming and bathing
284 II, 7. 4. 4 | Safety Promotion, 2008).~ ~Figure 7.21. Sports practiced at
285 II, 7. 4. 4 | also in this age group (Figure 7.22).~ ~Figure 7.22. Sports
286 II, 7. 4. 4 | age group (Figure 7.22).~ ~Figure 7.22. Sports practiced at
287 II, 7. 4. 5 | of “product” is involved (Figure 7.23), the importance of
288 II, 7. 4. 5 | protection is obvious.~ ~Figure 7.23: Category of products
289 II, 9 | Olausson et al, 1997).~ ~Figure 9.T1.1. Percentage of mothers
290 II, 9 | varies across Europe, as Figure 9.1c illustrates. This information
291 II, 9 | under 10% to almost 25%.~ ~Figure 9.T1.3. Rates of Smoking
292 II, 9 | disease (Fig.9.T1.4).~ ~ ~Figure 9.T1.4. Relationship between
293 II, 9. 1. 1 | Neonatal mortality~As shown in Figure 9.1.1.1, there has been
294 II, 9. 1. 1 | Foetal mortality~As Figure 9.1.1.2 illustrates, foetal
295 II, 9. 1. 1 | birth weight and preterm delivery~ ~Figure 9.1.1.3 presents rates of
296 II, 9. 1. 1 | with normal birth weight.~ ~Figure 9.1.1.3. Percentage of live
297 II, 9. 1. 2 | congenital heart disease (Figure 9.1.2.1), but an overall
298 II, 9. 1. 2 | prevalence has increased.~ ~Figure 9.1.2.1. Trends in the total
299 II, 9. 1. 2 | neonatal deaths, thus, this figure is probably considerably
300 II, 9. 1. 2 | anomalies. This average figure is almost certainly under-ascertained,
301 II, 9. 1. 2 | disease has been increasing (Figure 9.1.2.1), probably associated
302 II, 9. 1. 2 | documented in Chapter 8. Figure 9.1.2.2 shows the resulting
303 II, 9. 1. 2 | TOPFA) of 3.4 per 1 000.~ ~Figure 9.1.2.2. Trends in the total
304 II, 9. 1. 2 | Syndrome has slightly declined (Figure 9.1.2.2) to 1.0 per 1 000
305 II, 9. 1. 2 | over the subsequent decade (Figure 9.1.2.3). This has represented
306 II, 9. 1. 2 | in preventive policy.~ ~Figure 9.1.2.3. Trends in the total
307 II, 9. 1. 2 | Olausson et al, 1997).~ ~Figure 9.T1.1. Percentage of mothers
308 II, 9. 1. 2 | 2005 or most recent year~ ~Figure 9.T1.2a. Percent of mothers
309 II, 9. 1. 2 | older in EU15 and Norway~ ~Figure 9.T1.2b. Percent of mothers
310 II, 9. 1. 2 | varies across Europe, as Figure 9.1c illustrates. This information
311 II, 9. 1. 2 | under 10% to almost 25%.~ ~Figure 9.T1.3. Rates of Smoking
312 II, 9. 2. 3 | successfully treated in children.~ ~Figure 9.2.1a. Age-standardised
313 II, 9. 2. 3 | EUGLOREH Countries – Boys~ ~Figure 9.2.1b. Age-standardised
314 II, 9. 2. 3 | fact, Asthma UK gives a figure of 10% for childhood asthma,
315 II, 9. 2. 3(2) | Masoli et al an arbitrary figure of 50% of the prevalence
316 II, 9. 2. 3 | to be too fat, with this figure increasing to over 40% in
317 II, 9. 2. 3 | appropriately in terms of weight (Figure 9.2.2). Girls often perceive
318 II, 9. 2. 3 | actual weight or height.~ ~Figure 9.2.2. Young people dissatisfied
319 II, 9. 3. 1 | disease (Fig.9.T1.4).~ ~Figure 9.T1.4. Relationship between
320 II, 9. 3. 2 | al, 2002).~ ~As shown in Figure 9.3.2.1. the maternal mortality
321 II, 9. 3. 2 | countries~ ~As shown in Figure 9.3.2.2., which gives the
322 II, 9. 3. 2 | statistically significant.~ ~Figure 9.3.2.2. Maternal mortality
323 II, 9. 3. 2 | approaches.~ ~Caesarean Delivery~Figure 9.3.2.3. shows an increasing
324 II, 9. 3. 2 | Europe as illustrated in Figure 9.3.2.4. However, as these
325 II, 9. 3. 2 | routine follow-up services.~ ~Figure 9.3.2.4. Evolution of length
326 II, 9. 3. 3 | after the age of twenty.~ ~Figure 9.3.3.1. Young people who
327 II, 9. 3. 3 | 89% in Spain for girls (Figure 9.3.3.2). In almost all
328 II, 9. 3. 3 | in Belgium (Flemish).~ ~Figure 9.3.3.2. Young people who
329 II, 9. 4. 2 | service interventions.~ ~Figure 9.4.1. Ability to carry
330 II, 9. 4. 3 | of them related to falls (Figure 9.4.2). As much as about
331 II, 9. 4. 3 | experience a fall; this figure further increases for those
332 II, 9. 4. 3 | factor (WHO/HEN, 2004).~ ~Figure 9.4.2. Fatal injuries by
333 II, 9. 5. 1 | Europe and Romania, this figure may be up to five years
334 II, 9. 5. 3 | health risk behaviours.~ ~Figure 9.5.1. Percentage of deaths
335 II, 9. 5. 3 | European Commission, 2006).~ ~Figure 9.5.2. Unemployed persons
336 II, 9. 5. 3 | Statistics On-line, 2007). (See Figure 9.5.3) Carers can often
337 II, 9. 5. 3 | Age Concern, 2007b).~ ~Figure 9.5.3. Percentage of people
338 II, 9. 5. 3 | selected European countries~ ~Figure 9.5.4. Girls who drink any
339 II, 9. 5. 3 | been fully understood.~ ~Figure 9.5.5. Adults (15+) selecting ‘
340 III, 10. 1 | al, 1999).~ ~The model in Figure 10.1.1 illustrates the different
341 III, 10. 1 | and Whitehead, 1991).~ ~Figure 10.1.1. The model of health
342 III, 10. 1 | message is also conveyed by Figure 10.1.2 and, together with
343 III, 10. 1 | together with Table 10.1.1, by Figure 10.1.3.~ ~ ~ ~Figure 10.
344 III, 10. 1 | by Figure 10.1.3.~ ~ ~ ~Figure 10.1.3. The interaction
345 III, 10. 1 | women in the society.~ ~Figure 10.1.2 shows another model
346 III, 10. 1 | confounders or effect modifiers (Figure 10.1.2) (Rosner, 2000; Szklo,
347 III, 10. 1. 1 | behaviours and influences. Figure 10.1.3 is also applicable
348 III, 10. 1. 1 | heart rate increases.~ ~Figure 10.1.4 illustrates the described
349 III, 10. 1. 1 | disease determinants.~ ~Figure 10.1.4. Integration of nutrition
350 III, 10. 1. 1 | Green and Potvin, 2004) (Figure 10.1.2). Alcohol consumption
351 III, 10. 1. 1 | 1999; Pohorecky, 1991).~ ~Figure 10.1.5. illustrates examples
352 III, 10. 1. 1 | described associations.~ ~Figure 10.1.5. Examples of psychosocial
353 III, 10. 2. 1 | cessation.~ ~As shown in Figure 10.2.1.1.1, tobacco use
354 III, 10. 2. 1 | 2.1.1.1 and 10.2.1.2.~ ~Figure 10.2.1.1.1. Tobacco as a
355 III, 10. 2. 1 | diseases in all EU countries (Figure 10.2.1.1.4.).~Figure 10.
356 III, 10. 2. 1 | countries (Figure 10.2.1.1.4.).~Figure 10.2.1.1.4. Percentage of
357 III, 10. 2. 1 | in the 1980s, as shown in Figure 10.2.1.1.5. It is important
358 III, 10. 2. 1 | among European women.~ ~Figure 10.2.1.1.5. Trends in smoking
359 III, 10. 2. 1 | to three decades later (Figure 10.2.1.1.6).~ ~Figure 10.
360 III, 10. 2. 1 | later (Figure 10.2.1.1.6).~ ~Figure 10.2.1.1.6. Features of
361 III, 10. 2. 1 | than it was previously (Figure 10.2.1.2.1). Across the
362 III, 10. 2. 1 | between 1974 and 1978.~ ~Figure 10.2.1.2.1. Trends in recorded
363 III, 10. 2. 1 | times) of liver cirrhosis (Figure 10.2.1.2.2).~ ~Figure 10.
364 III, 10. 2. 1 | cirrhosis (Figure 10.2.1.2.2).~ ~Figure 10.2.1.2.2. Alcohol consumption
365 III, 10. 2. 1 | conditions and accidents, Figure 10.2.1.2.3.~ ~Figure 10.
366 III, 10. 2. 1 | accidents, Figure 10.2.1.2.3.~ ~Figure 10.2.1.2.3. Alcohol-attributable
367 III, 10. 2. 1 | die in the EU each year, Figure 10.2.1.2.4. This represents
368 III, 10. 2. 1 | disease later in life.~ ~Figure 10.2.1.2.4. The share of
369 III, 10. 2. 1 | alcohol-related problems (Figure 10.2.2.5) accounts for €
370 III, 10. 2. 1 | accounts for a further €59bn.~ ~Figure 10.2.1.2.5. The tangible
371 III, 10. 2. 1 | per capita consumption (Figure 10.2.1.2.6). The best predictors
372 III, 10. 2. 1 | income from alcohol taxes.~ ~Figure 10.2.1.2.6. Alcohol consumption
373 III, 10. 2. 1 | increase between 1995 and 1999 (Figure 10.2.3.1). An increase in
374 III, 10. 2. 1 | drugs has also occurred.~ ~Figure 10.2.1.3.1. Lifetime prevalence
375 III, 10. 2. 1 | used it in the last year (Figure 10.2.3.2) and over 7% (1.
376 III, 10. 2. 1 | month. For cocaine, the figure is 5.3% for average lifetime
377 III, 10. 2. 1 | ranges from 0.3% to 7.6%.~ ~Figure 10.2.1.3.2. Overview of
378 III, 10. 2. 1 | highest prevalence levels. See Figure 10.2.1.3.3 for trends in
379 III, 10. 2. 1 | cocaine use increasing7.~ ~ ~Figure 10.2.1.3.3. Trends in last
380 III, 10. 2. 1(7) | See Figure GPS-34 in the 2007 EMCDA
381 III, 10. 2. 1 | considerable variation in the EU (Figure 10.2.3.4), the reasons of
382 III, 10. 2. 1 | injectors in their lives.~ ~Figure 10.2.1.3.4. HIV prevalence
383 III, 10. 2. 1 | trends based on AIDS cases (Figure 10.2.1.3.5).~ ~Figure 10.
384 III, 10. 2. 1 | cases (Figure 10.2.1.3.5).~ ~Figure 10.2.1.3.5. AIDS incidence
385 III, 10. 2. 1 | more highly prevalent. See Figure 10.2.1.3.6 for national
386 III, 10. 2. 1 | injectors in their lives.~ ~Figure 10.2.1.3.6. Estimated HCV
387 III, 10. 2. 1 | often at a very high level. Figure 10.2.3.7 shows the trend
388 III, 10. 2. 1 | drug-related deaths in the EU15.~ ~Figure 10.2.1.3.7. Indexed long
389 III, 10. 2. 1(16)| See Figure DRD-1 in 2007 statistical
390 III, 10. 2. 1 | recently in many countries (Figure 10.2.3.8). From 1999 to
391 III, 10. 2. 1 | drug treatment in the EU.~ ~Figure 10.2.1.3.8. Trend in the
392 III, 10. 2. 1(19)| See Figure HSR-3 in the statistical
393 III, 10. 2. 1 | levels of physical activity (Figure 10.2.6.1). On average, only
394 III, 10. 2. 1 | likelihood decreased with age.~ ~Figure 10.2.1.6.1. Proportion of
395 III, 10. 2. 1 | Czech Republic and 25% in Portugal.~ ~Figure 10.2.1.6.2. Prevalence of
396 III, 10. 2. 1 | with age for both sexes.~ ~Figure 10.2.1.6.3. Average proportion
397 III, 10. 2. 1 | and the latest prevalence figure divided by the number of
398 III, 10. 2. 1 | Statistics Netherlands, 2006) (Figure 10.2.1.7.1).~ ~Figure 10.
399 III, 10. 2. 1 | Figure 10.2.1.7.1).~ ~Figure 10.2.1.7.1. Prevalence of
400 III, 10. 2. 1 | children’s height and weight.~ ~Figure 10.2.1.7.2 shows the prevalence
401 III, 10. 2. 1 | Currie et al, 2004).~ ~Figure 10.2.1.7.2. Prevalence of
402 III, 10. 2. 1 | Adults~ ~As illustrated in Figure 10.2.2.3, the prevalence
403 III, 10. 2. 1 | and 26.0% among women.~ ~Figure 10.2.1.7.3. Prevalence of
404 III, 10. 2. 1 | children and adolescents (Figure 10.2.1.7.4). For example,
405 III, 10. 2. 1 | Wang and Lobstein, 2006).~ ~Figure 10.2.1.7.4. Trends of overweight
406 III, 10. 2. 1 | Health, 1997). A similar figure was found for the World
407 III, 10. 2. 1 | 10.2.1.7.5, respectively. Figure 10.2.1.7.5 shows the gross
408 III, 10. 2. 1 | consumption of wine is reported in Figure 10.2.1.7.6.~ ~Figure 10.
409 III, 10. 2. 1 | in Figure 10.2.1.7.6.~ ~Figure 10.2.1.7.5. Gross human
410 III, 10. 2. 1 | products, 2004 (1 000 t)~ ~Figure 10.2.1.7.5. Trends in gross
411 III, 10. 2. 1 | 1995-2002 (1995=100)~ ~Figure 10.2.1.7.6. Average annual
412 III, 10. 2. 1 | underlying scientific data (Figure 10.2.1.7.7).~ ~Figure 10.
413 III, 10. 2. 1 | data (Figure 10.2.1.7.7).~ ~Figure 10.2.1.7.7. FBDG for different
414 III, 10. 3. 1 | is possible as shown in Figure 8.1.1.1.~ ~Figure 10.3.1.
415 III, 10. 3. 1 | shown in Figure 8.1.1.1.~ ~Figure 10.3.1.1. The percentage
416 III, 10. 3. 1 | the logarithmic scale of Figure 8.1.1.2. It was also estimated
417 III, 10. 3. 1 | exposure (Babisch, 2006).~ ~Figure 10.3.1.2. The environmental
418 III, 10. 3. 2 | contaminated products.~ ~Figure 10.3.2.1. Life cycle of
419 III, 10. 3. 2 | between 1995 and 2005 (Figure 10.3.2.2). The production
420 III, 10. 3. 2 | was 212 million tonnes (Figure 10.3.2.3), 9.3%of which
421 III, 10. 3. 2 | environment (ASEF, 2006).~ ~Figure 10.3.2.2. Production volumes
422 III, 10. 3. 2 | Member States 1995–2005~ ~Figure 10.3.2.3. Production of
423 III, 10. 3. 2 | the study summarized in Figure 10.3.2.4 shows decreasing
424 III, 10. 3. 2 | flame retardants (PBDE).~ ~Figure 10.3.2.4. Persistent Organic
425 III, 10. 3. 2 | polychlorinated naphthalenes (PCN) (figure 10.3.2.4; note different
426 III, 10. 3. 3 | occurring throughout Europe (Figure 10.3.3.1). However, two
427 III, 10. 3. 3 | may not be irreversible.~ ~Figure 10.3.3.1. Proportion of
428 III, 10. 3. 4 | affected are included in the figure. Accidents include the following
429 III, 10. 3. 4 | expected excess death rate.~ ~Figure 10.3.4.1. The distribution
430 III, 10. 3. 4 | effects on human health (Figure 10.3.4.2). The total economic
431 III, 10. 3. 4 | following flooding events .~ ~Figure 10.3.4.2. Frequency of floods
432 III, 10. 4. 1 | of 40 μg/m3 is exceeded.~Figure 10.4.1.1 presents the total
433 III, 10. 4. 1 | the last available year); Figure 10.4.1.2 shows the changes
434 III, 10. 4. 1 | living children in cities.~ ~Figure 10.4.1.1. Percentage of
435 III, 10. 4. 2 | magnitude of the estimated figure. The Opinion gave basic
436 III, 10. 4. 2 | of Regulation 396/2005 (Figure 1).~ ~Figure 10.4.2.1. Entry
437 III, 10. 4. 2 | Regulation 396/2005 (Figure 1).~ ~Figure 10.4.2.1. Entry into force
438 III, 10. 4. 2 | were held in 16 “rounds” (Figure 10.4.2.2).~ ~ ~Figure 10.
439 III, 10. 4. 2 | Figure 10.4.2.2).~ ~ ~Figure 10.4.2.2. Pesticides Peer
440 III, 10. 4. 2 | Ireland, performs its role (Figure 1). FVO inspectors carry
441 III, 10. 4. 3 | Valent et al, 2004).~ ~Figure 10.4.3.1. Deaths among children
442 III, 10. 4. 3 | illness from 2000 to 2005 (Figure 10.4.3.2).~ ~Figure 10.4.
443 III, 10. 4. 3 | 2005 (Figure 10.4.3.2).~ ~Figure 10.4.3.2. Number of reported
444 III, 10. 4. 3 | rising from 58% to 80% (Figure 10.4.3.3). According to
445 III, 10. 4. 3 | of safe drinking-water.~ ~Figure 10.4.3.3. Percentage of
446 III, 10. 4. 3 | sanitation systems (see Figure 10.4.3.2).~ ~A special case
447 III, 10. 4. 3 | population in European countries (Figure 10.4.3.4) were connected
448 III, 10. 4. 3 | increase from 1995 to 2003.~ ~Figure 10.4.3.4. Changes over time
449 III, 10. 4. 4 | product” is involved (see Figure 7.23), the importance of
450 III, 10. 4. 5 | mandatory European standards (Figure 10.4.5.1.1. A and B) (EEA,
451 III, 10. 4. 5 | A and B) (EEA, 2008).~ ~Figure 10.4.5.1.1.a. Bathing water.
452 III, 10. 4. 5 | directives in coastal water~ ~Figure 10.4.5.1.1.b. Bathing water.
453 III, 10. 4. 5 | storage of chemicals (see Figure 10.4.5.2.1; EEA, 2007a).~ ~
454 III, 10. 4. 5 | playgrounds (EEA, 2007b).~ ~Figure 10.4.5.2.1. Overview of
455 III, 10. 4. 5 | per capita per year. This figure has been calculated based
456 III, 10. 4. 5 | volumes of municipal waste (Figure 10.4.5.2.2). However, the
457 III, 10. 4. 5 | re-unification of Germany.~ ~Figure 10.4.5.2.2a. Total waste
458 III, 10. 4. 5 | sector, 2004 (EECCA 2004)~ ~Figure 10.4.5.2.2b. Total waste
459 III, 10. 4. 5 | sector, 2004 (EU-10, 2004)~ ~Figure 10.4.5.2.2c. Total waste
460 III, 10. 4. 5 | Russia the dominant producer (Figure 10.4.5.2.3). The large differences
461 III, 10. 4. 5 | not entirely comparable.~ ~Figure 10.4.5.2.3. Hazardous waste
462 III, 10. 4. 5 | Soil contamination~ ~Figure 10.4.5.2.4. Overview of
463 III, 10. 4. 5 | contaminated sites in Europe~ ~Figure 10.4.5.2.5. Breakdown of
464 III, 10. 4. 5 | contamination per country~ ~Figure 10.4.5.2.6. Detailed analysis
465 III, 10. 4. 5 | contamination per country~ ~Figure 10.4.5.2.7. Overview of
466 III, 10. 4. 5 | remediated sites are available (Figure 10.4.5.2.4).~ ~The distribution
467 III, 10. 4. 5 | total investigated sites (Figure 10.4.5.2.5).~ ~At industrial
468 III, 10. 4. 5 | in national inventories ((Figure 10.4.5.2.6).~ ~The range
469 III, 10. 4. 5 | contaminants in Europe (Figure 10.4.5.2.7). These estimates
470 III, 10. 5. 1 | countries fall short of this figure and may provide public water
471 III, 10. 5. 1 | 20% of the population.~ ~Figure 10.5.1.1. Proportion of
472 III, 10. 5. 1 | WHO, 2005; EEA, 2006b).~ ~Figure 10.5.1.2. Concentrations
473 III, 10. 5. 1 | socio-economic groups.~ ~Figure 10.5.1.3. Housing problems
474 III, 10. 5. 1 | the indicated average.~ ~Figure 10.5.1.4. Crowding by income
475 III, 10. 5. 2 | rural settlements structures.~ ~Figure 10.5.2.1. Population distribution
476 III, 10. 5. 2 | Figures 10.5.2.2-10.5.2.4).~ ~Figure 10.5.2.2. Complaints by
477 III, 10. 5. 2 | environmental conditions~ ~Figure 10.5.2.3. Complaints due
478 III, 10. 5. 2 | urban and rural settings~ ~Figure 10.5.2.4. Complaint about
479 III, 10. 5. 2 | for males and females.~ ~Figure 10.5.2.5. Correlation of
480 III, 10. 5. 2 | rural settlements, males~ ~Figure 10.5.2.6. Correlation between
481 III, 10. 5. 2 | the older population.~ ~Figure 10.5.2.7. Life expectancy
482 III, 10. 5. 2 | rural settings in Lithuania, 2006~ ~Figure 10.5.2.8. Mortality rates
483 III, 10. 5. 2 | the new member States.~ ~Figure 10.5.2.9. Self-reported
484 III, 10. 5. 2 | joined the EU in 2004.~ ~Figure 10.5.2.10. Long-standing
485 III, 10. 5. 2 | and preventive actions.~ ~Figure 10.5.2.11. Health problems
486 III, 10. 5. 2 | prevalent in rural settings.~ ~Figure 10.5.2.12. Infection prevalence
487 III, 10. 5. 3 | elements of work economies. Figure 10.5.3.1 summarizes the
488 III, 10. 5. 3 | economically inactive.~ ~Figure 10.5.3.1. Work status of
489 III, 10. 6. 1 | France and 28% in Belgium.~ ~Figure 10.6.1. Frequency of contact
490 III, 10. 6. 1 | Currie et al., 2008).~ ~Figure 10.6.2. 15-year old girls
491 III, 10. 6. 1 | friends of the same gender~ ~Figure 10.6.3. 15-year old boys
492 III, 10. 6. 1 | Currie et al., 2008).~ ~Figure 10.6.4. Use of electronic
493 III, 10. 6. 1 | Van Dijk et al, 2005).~ ~Figure 10.6.5. Exposures to assaults
494 III, 10. 6. 2 | inequalities in men than in women (Figure 10.6.2.1). Inequalities
495 III, 10. 6. 2 | those due to education (Figure 10.6.2.2). These inequalities
496 III, 10. 6. 2 | of mortality decline.~ ~Figure 10.6.2.1. Educational inequalities
497 III, 10. 6. 2 | European Countries per cause~ ~Figure 10.6.2.2. Inequalities in
498 III, 10. 6. 3 | carried out in Chapter 7 (See figure 7.17).~ ~Contact crimes:
499 III, 10. 6. 3 | than for other offences. Figure 10.6.3.1. shows the results.
500 III, 10. 6. 3 | Hungary and Spain (below 2%). Figure 10.6.3.1. shows national
